NCCN Updated Guidelines for Breast Cancer: A Payer's Perspective

Download PDF
Gary Rice, RPh, MS, MBA

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: August 14th, 2009 - August 14th, 2010

This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This activity was developed for physicians, pharmacy directors, P&T Committee members, managed care pharmacists, oncology pharmacists, and other key stakeholders who wish to enhance their knowledge concerning the implementation of a value-based benefit design for cancer care.

Learning Objectives
At the completion of this activity participants should be able to:

  • Identify the intersection of epidemiologic shifts in the American cancer patient population, new cancer drug costs, and new diagnostic measures, on achieving value based clinical treatment
  • Recognize the role of value (cost, quality, access) in the new value-based healthcare system and the incentives of payers and purchasers to meet each of these 3 aspects of value in cancer care
  • Understand how NCCN clinical practice treatment guidelines are aiding all stakeholders in attaining value based cancer care amidst rising new product costs
  • Incorporate value-based care in the treatment of breast cancer

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of the University of Cincinnati, Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.

Faculty Disclosures
Gary Rice, RPh, MS, MBA has nothing to disclose.

*Content will include non-FDA-approved uses.

The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Trade names used in this supplement are for the learner's reference only. No promotion of or bias toward any product should be inferred.

Related Items
Evolving Role of Biologics: A Payer’s and Provider’s Perspective
Gary Rice, RPh, MS, MBA
Supplements published on April 29, 2011
Value-Based Oncology Benefit Design™ Balancing Cost, Quality, and Access in Cancer Care
Gary M. Owens, MD, Al B. Benson III, MD, FACP, Gary Rice, RPh, MS, MBA
Supplements published on June 30, 2009
Last modified: March 24, 2014